Alector, Inc. (ALEC)
ALEC Stock Price Chart
Explore Alector, Inc. interactive price chart. Choose custom timeframes to analyze ALEC price movements and trends.
ALEC Company Profile
Discover essential business fundamentals and corporate details for Alector, Inc. (ALEC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Feb 2019
Employees
175.00
Website
https://www.alector.comCEO
Arnon Rosenthal
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Financial Timeline
Browse a chronological timeline of Alector, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.40, while revenue estimate is $3.49M.
Earnings released on 7 Aug 2025
EPS came in at -$0.30 surpassing the estimated -$0.45 by +33.33%, while revenue for the quarter reached $7.87M , beating expectations by +180.73%.
Earnings released on 8 May 2025
EPS came in at -$0.41 surpassing the estimated -$0.44 by +6.82%, while revenue for the quarter reached $3.67M , missing expectations by -13.55%.
Earnings released on 26 Feb 2025
EPS came in at -$0.02 surpassing the estimated -$0.61 by +96.72%, while revenue for the quarter reached $54.24M , beating expectations by +165.82%.
Earnings released on 6 Nov 2024
EPS came in at -$0.43 surpassing the estimated -$0.53 by +18.87%, while revenue for the quarter reached $15.34M , missing expectations by -5.76%.
Earnings released on 7 Aug 2024
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $15.08M , beating expectations by +4.74%.
Earnings released on 8 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.48 by +20.83%, while revenue for the quarter reached $15.89M , beating expectations by +7.39%.
Earnings released on 27 Feb 2024
EPS came in at -$0.49 surpassing the estimated -$0.80 by +38.75%, while revenue for the quarter reached $15.19M , beating expectations by +57.57%.
Earnings released on 7 Nov 2023
EPS came in at -$0.53 surpassing the estimated -$0.65 by +18.46%, while revenue for the quarter reached $9.11M , missing expectations by -5.51%.
Earnings released on 3 Aug 2023
EPS came in at $0.02 surpassing the estimated -$0.82 by +102.44%, while revenue for the quarter reached $56.21M , beating expectations by +1.28K%.
Earnings released on 4 May 2023
EPS came in at -$0.55 surpassing the estimated -$0.75 by +26.67%, while revenue for the quarter reached $16.55M , beating expectations by +107.90%.
Earnings released on 28 Feb 2023
EPS came in at -$0.63 falling short of the estimated -$0.54 by -16.67%, while revenue for the quarter reached $14.44M , missing expectations by -52.10%.
Earnings released on 8 Nov 2022
EPS came in at -$0.56 falling short of the estimated -$0.43 by -30.23%, while revenue for the quarter reached $14.85M , missing expectations by -52.97%.
Earnings released on 4 Aug 2022
EPS came in at $0.12 surpassing the estimated -$0.47 by +125.53%, while revenue for the quarter reached $79.85M , beating expectations by +159.10%.
Earnings released on 5 May 2022
EPS came in at -$0.54 falling short of the estimated $0.37 by -245.95%, while revenue for the quarter reached $24.47M , missing expectations by -76.23%.
Earnings released on 24 Feb 2022
EPS came in at -$0.68 falling short of the estimated -$0.13 by -423.08%, while revenue for the quarter reached $13.99M , missing expectations by -83.31%.
Earnings released on 4 Nov 2021
EPS came in at $1.49 falling short of the estimated $2.09 by -28.71%, while revenue for the quarter reached $182.41M , beating expectations by +15.38%.
Earnings released on 3 Aug 2021
EPS came in at -$0.69 matching the estimated -$0.69, while revenue for the quarter reached $6.57M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$0.66 surpassing the estimated -$0.68 by +2.94%, while revenue for the quarter reached $4.11M , missing expectations by -47.97%.
Earnings released on 25 Feb 2021
EPS came in at -$0.66 falling short of the estimated -$0.61 by -8.20%, while revenue for the quarter reached $4.85M , missing expectations by -41.74%.
Earnings released on 10 Nov 2020
EPS came in at -$0.67 falling short of the estimated -$0.54 by -24.07%, while revenue for the quarter reached $5.90M , beating expectations by +27.91%.
ALEC Stock Performance
Access detailed ALEC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.